Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28859329 | 0.84 | KDM5A (0.36) | KDM5A | |
| SCHEMBL23612150 | 0.77 | KDM5A (0.36) | KDM5A | |
| SCHEMBL18341568 | 0.77 | KDM5A (0.34) | KDM5A | |
| SCHEMBL22098043 | 0.77 | KDM5A (0.32) | KDM5A | |
| SCHEMBL25882396 | 0.75 | IRAK4 (0.39) | KDM5A | |
| SCHEMBL17199541 | 0.75 | F2 (0.35) | — | |
| SCHEMBL28214771 | 0.75 | KDM5A (0.38) | KDM5A | |
| SCHEMBL31262823 | 0.74 | FFAR1 (0.45) | — | |
| SCHEMBL173506 | 0.74 | — | — | |
| SCHEMBL2574462 | 0.73 | KIT (0.48) | KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12421213-B2 | Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20250115586-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12098142-B2 | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-09-24 | — | — | US | disclosed |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-11981663-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-05-14 | — | — | US | disclosed |
| US-20240083881-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-03-14 | — | — | US | disclosed |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| CN-113227074-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods | 凌科药业(杭州)有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020119819-A1 | BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2020-06-18 | — | — | WO | disclosed |
| US-20190135836-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135836-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10280184-B2 | Heterocyclic kinase inhibitors | ABBVIE INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-10280184-B2 | Heterocyclic kinase inhibitors | ABBVIE INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. | 2017-04-27 | — | — | US | disclosed |
| WO-2015158283-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083881-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | KDM5A 305/4885 |
| US-10280184-B2 | Heterocyclic kinase inhibitors | MAP3K1, MAP3K20, MAP3K19 | KDM5A 1333/4885 |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK1, JAK3, JAK2 | KDM5A 1992/4885 |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | KDM5A 1333/4885 |
| US-20250115586-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | KDM5A 305/4885 |
| US-12421213-B2 | Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | KDM5A 360/4885 |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | KDM5A 360/4885 |
| US-12098142-B2 | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | JAK1, JAK3, JAK2 | KDM5A 203/4885 |
| US-20190135836-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | KDM5A 1377/4885 |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK2, JAK1, JAK3 | KDM5A 360/4885 |
| US-11981663-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | KDM5A 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.